Abstract: The present application is directed to radiolabeled imaging agents comprising a radiolabel, and a substrate, pharmaceutical compositions comprising radiolabeled imaging agents, and methods of using the radiolabeled imaging agents. The present application is further directed to methods of preparing the radiolabeled imaging agent. Such imaging agents can used in imaging studies, such as Positron Emitting Tomography (PET) or Single Photon Emission Computed Tomography (SPECT).

Abstract: A process is provided herein for preparing molecularly imprinted polymers for detecting a target analyte by Reversible Addition Fragmentation Chain Transfer (RAFT). The process includes providing a complex having the formula L3M wherein L is a ?-diketone ligand containing a chain transfer moiety and L3 can be the same or different ligands, and M is a lanthanide element; reacting the complex with the target analyte to provide an adduct containing the target analyte; co-polymerizing the adduct with a monomer and cross-linking agent to provide a polymer; and removing the target analyte from the polymer to provide the molecularly imprinted polymer.

Abstract: Disclosed herein is a nanoporous hybrids formed by covalent bonding between a crystalline organic-inorganic hybrid and a gigantic mesoporous metal oxide, containing organic groups on the surface thereof, having a size of 10 nm or more. Since the covalently-bonded hybrid nanoporous composite has a large surface area, a multiple microporous structure, a large pore volume and includes an organic-inorganic hybrid having backbone flexibility, the covalently-bonded hybrid nanoporous composite can be used as materials for storing liquids and gases, such as hydrogen, methane and the like, and can be used as adsorbents, separating materials, catalysts, and the like. Further, the covalently-bonded hybrid nanoporous hybrids can be used in the application fields of biomolecule supporting, drug delivery, harmful material removal, nanoparticle supporter, sensors, catalysis, adsorbents, fluorescent materials, solar cells, and the like.

Abstract: The present invention relates to diethylenetriamine pentaacetic acid (DTPA) derivates and metal complexes thereof, and radiation sources and contrast agents including the metal complexes. More particularly, the present invention relates to DTPA derivatives, which contain iodine and are useful as contrast agents for diagnosing renal function, metal complexes of the DTPA derivatives with 99mTc, 166Ho, 111In, 90Y, 153Sm, 186Re, 188Re, 68Ga, or 177Lu, which are useful as liquid radiation sources for treating vascular stenosis and contrast agents for diagnosing renal function, and radiation sources and contrast agents including the metal complexes. The DTPA derivatives and metal complexes thereof are safe because the metal complexes are excreted via the kidneys and bladder within several minutes from the time of use as liquid radiation sources for treating vascular stenosis, and are cost-effective because they are potentially useful as contrast agents and as agents for diagnosing renal function.

Abstract: The present invention relates to a process for producing nanosize to microsize particles of compounds of the rare earth metals and other transition metals and also for producing colloid-chemically stable sols of these particles.

Abstract: A water-stable and water-soluble ceramic precursor is provided, containing at least one Group III element. Also, a metal acid salt complex is provided comprising (1) bismuth, lanthanum, and titanium, and (2) a polyether acid. In addition, methods are provided for preparing the Group III metal acid salt complex and the Bi, La, Ti acid salt complex comprising a bismuth polyether acid salt complex, a lanthanum polyether acid salt complex, and a titanium polyether acid salt complex. Finally, devices that include lanthanum-doped bismuth titanate as the active component are provided, as well as a water-stable and water-soluble gallium polyether acid complex.

Abstract: The present invention is directed to methods for making metal oxide compositions, specifically, metal oxide compositions having high surface area, high metal/metal oxide content, and/or thermal stability with inexpensive and easy to handle materials. In one embodiment, the present invention is directed to methods of making metal and/or metal oxide compositions, such as supported or unsupported catalysts. The method includes combining a metal precursor with an organic acid to form a mixture and calcining the mixture for a period of time sufficient to form a metal oxide material.

Abstract: The present invention relates to an red luminescent ink composition exhibiting adequate and stable emission intensity under irradiation of ultraviolet rays and high solubility for a resin and an organic solvent. The ink composition of the present invention contains a luminous compound represented by the following formula (1): wherein R is a perfluoroalkyl group having 2 to 20 carbons, L1 and L2 are the same or different and are sulfoxide having a substituted or unsubstituted aryl group or a substituted or unsubstituted an alkyl group.

Abstract: The present invention relates to a silica particle comprising at least one complex of at least one lanthanide and of at least one ligand of formula (A) in which Z1, Z2 and Z3, which may be identical or different, each represent a group bearing an atom bearing a lone pair and/or a negative charge; R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and R12, which may be identical or different, each represent a hydrogen, an optionally substituted alkyl radical, an optionally substituted aryl radical, a halogen, a group —OR13 or a group —SR13, with R13 representing H, an optionally substituted alkyl group or an optionally substituted aryl group.

Abstract: Organometallic complexes comprising a trivalent lanthanide metal ion complexed with one or more polydentate ligands containing one or more pyrazolyl-derived groups, such as trispyrazolyl borate species, are useful in light emitting materials e.g., in electroluminescent flat panel displays. In the complexes, several classes of which are novel, a coordinate bond is formed between the metal and one of the nitrogen atoms of the pyrazolyl rings.

Abstract: The present invention is directed to yttrium compositions and methods for making such metal oxide compositions, specifically, metal oxide compositions having high surface area, high metal/metal oxide content, and/or thermal stability with inexpensive and easy to handle materials.

Abstract: [Problems] To impart an antiglare effect to a laminated glass making use of a polyvinyl butyral resin as an intermediate film without coloring the same. [Means for Solving Problems] There is provided an intermediate film of laminated glass, comprised of a resin composition containing a polyvinyl butyral resin, a plasticizer and a neodymium compound compatible with plasticized resin. The neodymium compound is preferably a neodymium salt of one or more types of polyvalent ester monocarboxylic acids, or a mixed neodymium salt of a polyvalent ester monocarboxylic acid and an aliphatic or aromatic monocarboxylic acid.

Abstract: The present invention relates to a compound comprising, firstly a component for targeting at least one chemokine receptor and, secondly, a detection component capable of being identified by a medical imaging method.

Abstract: A rapid, simple and versatile metal organic framework molecule (MOF) synthesis method particularly adapted to make non-linear MOFs includes heating MOF precursors, such as a metal or metal oxide and an organic ligand, in a microwave oven for a period sufficient to achieve crystallization. Microwave-assisted MOF synthesis yields high quality MOF crystals in a reaction time ranging from about 5 seconds to about 2.5 minutes, compared to hours and days required in conventional solvothermal and hydrothermal methods. In addition, microwave assisted methods provide MOF materials with uniform crystal size and well-defined shape. Further, microwave synthesis of MOFs allows the size and shape of MOF crystals to be tailored for use in a wide range applications by manipulating reaction conditions. Secondary growth processes may also be employed to grow larger crystals using seeds obtained from microwave-assisted synthesis methods.

Abstract: The present invention provides a process of preparation of naphthochlorins and other chlorins with annelated ring systems useful for photodynamic therapy and the compounds themselves. The method for producing naphthochlorin compounds include contacting compounds such as meso-(2?-hydroxymethyl)phenyl porphyrin or meso-(2?-N,N,N-trialkylaminomethyl)phenyl porphyrin precursors with at least one acid catalyst at sufficient temperature for a sufficient time to yield the desired conversion. In a similar manner chlorins possessing annelated ring systems may be made from compounds such as meso-(2?-hydroxymethyl)aryl porphyrins or meso-(2?-N,N,N-trialkylaminomethyl)phenyl porphyrin. The procedures described herein provide new routes for synthesizing naphthochlorins and chlorins with annelated ring systems.

Abstract: Systems, including compositions, kits, and methods, particularly for photoluminescence applications. The systems may include, among others, (1) organic chelators, (2) complexes between the chelators and lanthanide ions, and (3) precursors, derivatives, and uses thereof. The chelators may include a 1,4,7,10-tetraazacyclododecane ring system, for example, having the formula: Here, R1, R2, and R3 are substituents of the tetraazacyclododecane ring system, that is further substituted at the 10-position by a sensitizer Z that is typically a polyheterocyclic ring system. The organic chelator may be capable of forming a luminescent complex with a lanthanide ion, and is optionally further substituted by a reactive functional group or a conjugated substance. The resulting lanthanide complex may be useful in luminescence-based assays, such as energy transfer assays, among others.

Abstract: The present invention is directed to metal chelating conjugates for use as metallopharmaceutical diagnostic or therapeutic agents. Specifically, conjugates of the present invention include one or more carriers, a linker, and a metal coordinating moiety comprising a substituted phenyl, pyridyl, or pyrimidyl derivative.

Abstract: The present invention relates to a process for preparing a porous metal organic framework, which comprises the step: Reaction of at least one metal compound with at least one at least bidentate organic compound which can coordinate to the metal, where the metal is ScIII, YIII or a trivalent lanthanide and the organic compound has at least two atoms which are selected independently from the group consisting of oxygen, sulfur and nitrogen and via which the organic compound can coordinate to the metal, in the presence of a nonaqueous organic solvent, with the reaction being carried out with stirring and at a pressure of not more than 2 bar (absolute). The invention further relates to porous metal organic frameworks which have been prepared by this process and their use.

Abstract: A compound having superior solubility and suitable for a liposome contrast medium selective for a lesion such as vascular diseases is provided which is represented by the following general formula (I) wherein R1, R2 and R3 independently represent an alkyl group or an alkenyl group having 8 to 25 carbon atoms; X represents —O—, or —N(Z)- (Z represents hydrogen atom, or an alkyl group having 1 to 3 carbon atoms); and L represents a divalent bridging group constituted by atoms selected from the group consisting of carbon atom, hydrogen atom, oxygen atom, nitrogen atom and sulfur atom; Ch represents a functional group represented by the following general formula (II), and in the general formula (II), any one of the hydrogen atom Ha, Hb, Hc, Hd, He, and Hf is substituted with L.

Abstract: The invention concerns a transition metal coordination complex of general formula (I) {[M(X)]C(H2O)n}p wherein: M represents an element belonging to the lanthanide group; and L represents a decadentate chromophore ligand of general formula (II). R1, R2, R3 and R4 independently represent hydrogen or an alkyl or aryl radical. A1, A2, A3 and A4 independently represent a structure of general formula (III). U1, U2 and U3 independently represent C or N, and R5, R6 and R7 independently represent hydrogen, an alkyl or aryl radical. Y represents C, O, S, P or N, and m is an integer representing free valences of Y. R8 represents independently hydrogen, an alkyl or aryl radical. X represents a counter-ion, and n represents hydrating water molecules. p represents monomers. H2O represents the hydrating water molecules. The invention also concerns a method for preparing such a ligand.

Abstract: An article of manufacture marked with compositions comprising rare earth metal compounds which, due to their luminescence when irradiated with UV light, are suitable in particular for the marking of security-relevant items, such as documents or data carriers.

Abstract: The present invention is to provide a light emitting device which can generate high-intensity light emission, using a fluorescent material containing a rare earth element ion complex and being excellent in durability and also provide the fluorescent material to be used therein. The present invention relates to a light emitting device comprising a semiconductor light emitting element which emits light within the region from near-ultraviolet light to visible light, and a fluorescent material which contains a rare earth element ion complex having an aromatic ring-containing Bronsted acid ion with a pKa value of 7 or less as a ligand and emits light by the action of light of the semiconductor light emitting element.

Abstract: The invention relates to the subjects characterized in the patent claims, namely metal chelates having a perfluorinated PEG radical, processes for their preparation, and their use, processes for their preparation and their use in NMR and X-ray diagnosis, radiodiagnosis and radiotherapy, and in MRT lymphography.

Abstract: A cationic Group 3 or Lanthanide metal complex for coordination polymerization of olefins is disclosed. The precursor metal complex is stabilized by an anionic multidentate ancillary ligand and two monoanionic ligands. The ancillary ligand and the transition metal form a metallocycle having at least five primary atoms, counting any ?-bound cyclopentadienyl group in the metallocycle as two primary atoms. Olefin polymerization is exemplified.

Abstract: An alkoxyalcohol adduct of rare earth monocarboxylate has the formula (I): M(R2—COO)3.(R1O(CH2)nOH)p ??(I) in which M is a rare earth element such as Pr, Nd, Pm, Sm, Eu, Gd, Tb, Dy, Ho, Er, Tm, Yb and Lu; R1 is an aliphatic hydrocarbon group having 1 to 4 carbon atoms or a substituted aliphatic hydrocarbon group having 3 to 6 carbon atoms; R2 is a hydrogen atom or an aliphatic hydrocarbon group having 1 to 4 carbon atoms which has or does not have a substituent; n is 2 or 3; and p is a number in the range of 0.5 to 3.

Abstract: Backbone-substituted 1,4,7,10-tetraaza cyclododecane-N,N?,N?,N??-tetraacetic acid compounds, metal complexes thereof, compositions thereof, conjugates thereof, and methods of use in diagnostic imaging and treatment of a cellular disorder.

Abstract: Novel metal-chelate complexes comprising aminocarboxylate ligands including substituted aromatic amide moieties, such as those having the formula wherein R13, A1, R1 and R2 are as defined herein, are disclosed.

Abstract: The invention relates to compounds, to the complexes they form with a lanthanide, and to the use of the complexes for fluorescence marking or NMR imaging. The complex consists of an Ln ion and a ligand R2-C(X-R1)(R3)-NR4R5. R1 is a functional group, X is a single bond or a hydrocarbon-based chain consisting of at least one alkylene or alkenylene group optionally comprising at least one hetero atom or an arylene. R2 is an anionic group A2 or a C1-C4 alkylene or alkenylene group bearing at least one such group A2 and optionally comprising at least one hetero atom. R3 is H or a C1-C5 alkylene or alkenylene group optionally containing at least one hetero atom, and optionally bearing at least one anionic group A3. R4 is a substituent with light-absorbing properties that forms chelate rings with Ln. R5 is a substituent that forms chelate rings with Ln.

Abstract: A metalorganic complex composition comprising a metalorganic complex selected from the group consisting of: metalorganic complexes comprising one or more metal central atoms coordinated to one or more monodentate or multidentate organic ligands, and complexed with one or more complexing monodentate or multidentate ligands containing one or more atoms independently selected from the group consisting of atoms of the elements C, N, H, S, O and F; wherein when the number of metal atoms is one and concurrently the number of complexing monodentate or multidentate ligands is one, then the complexing monodentate or multidentate ligand of the metalorganic complex is selected from the group consisting of beta-ketoiminates, beta-diiminates, C2-C10 alkenyl, C2-C15 cycloalkenyl and C6-C10 aryl.

Abstract: The present invention relates to compounds and related technetium and rhenium complexes thereof which are suitable for imaging or therapeutic treatment of tumors, e.g., carcinomas, melanomas and other tumors. In another embodiment, the invention relates to methods of imaging tumors using radiolabeled metal complexes. Preferred radiolabeled complexes for imaging tumors include technetium and rhenium complexes. The high tumor uptake and significant tumor/nontumor ratios of the technetium complexes of the invention indicate that such small technetium-99m-based molecular probes can be developed as in-vivo diagnostic agents for melanoma and its metastases. In yet another embodiment, the invention relates to methods of treatment of tumors using a radiolabeled metal complex as a radiopharmaceutical agent to treat the tumor.

Abstract: This invention provides a fluorescent complex possessing excellent durability and luminous intensity, and a lighting system utilizing the same. The fluorescent complex comprises a rare earth ion and a ?-diketone ligand. In the fluorescent complex, the ?-diketone ligand comprises a ?-diketone skeleton, a fluoroalkyl group, and an electron donative linking group for linking the ?-diketone skeleton to the fluoroalkyl group. The fluorescent complex can be utilized in a lighting system. The rare earth ion is preferably a lanthanoid ion, particularly preferably a europium or terbium ion. When the ?-diketone ligand further comprises an aromatic group, the luminous intensity can be further improved.

Abstract: The invention concerns a method for preparing a particle comprising a lanthanide chelate, comprising polymerizing a lanthanide chelate derivative with one or more monomers, wherein the lanthanide chelate derivative has the formula M-L-Y (I), wherein Y is a lanthanide chelate; L is a linker and M is a polymerizable moiety. The invention concerns also the novel lanthanide chelate derivative M-L-Y (I). Further, the invention concerns a novel particle comprising a lanthanide chelate covalently bound to an organic polymer or copolymer via a linker.

Abstract: The present invention provides an improved, economical and environmentally benign process for metal complexes of acetylacetone having the general formula, M(acac)n wherein M is a metal cation selected from the group consisting of Fe, Co, Ni, Cu, Zn, Al, Ca, Mg, Mo, Ru, Re, U, Th, Ce, Na, K, Rb, Cs, V, Cr, and Mn etc., n is an integer which corresponds to the electrovalence of M, are obtained by reacting the corresponding metal hydroxide, metal hydrated oxide or metal oxide with a stoichiometric amount of acetylacetone and separating the product.

Abstract: Disclosed are methods of using a transparent, luminescent polymer for transparent marking and/or labeling for identity verification purposes. Also disclosed are sheets, films, markers, labels and taggants comprising transparent, luminescent polymers. Also disclosed are articles labeled with a transparent, luminescent polymer. This invention particularly relates to use of transparent, luminescent polymer compositions comprising ethylene (meth)acrylic acid copolymers and rare earth ions and transparent, luminescent polymer compositions comprising methyl (meth)acrylate/(meth)acrylic acid copolymers, fatty acids and rare earth ions for these purposes.

Abstract: A cycloalkyl triamine pentacarboxylate compound coordinating to a metal ion to form a high stability metal complex in serum is provided. The metal complex of the present invention can be used as a contrast agent for magnetic resonance imaging (MRI).

Abstract: New types of hydroxamic acid-based bifunctional chelators are provided. These chelators are designed to chelate metal ions that can be detected either by their paramagnetic or radioactive properties. Conjugation with peptides or protein can be achieved by the presence of a linker moiety in the molecular structure of these chelators.

Abstract: Described are new cascade polymer complexes, compositions containing them and use of the complexes in diagnosis and therapy, particularly for magnetic resonance imaging and computer tomography imaging.

Abstract: A method is described for the manufacture of hydrotalcites by using at least one compound of a bivalent metal (Component A) and at least one compound of a trivalent metal (Component B), wherein at least one of these components is not used in the form of a solution, characterized in that a) at least one of the Components A and/or B which is not used in the form of a solution, shortly before or during mixing of the components, and/or b) the mixture containing the Components A and B is subjected to intensive grinding until an average particle size (D50) in the range of approx. 0.1 to 5 ?m is obtained, and optionally, after aging treatment or hydrothermal treatment, the resulting hydrotalcite product is separated, dried, and optionally calcinated.

Abstract: The metal complexes of general formula I in which Hal stands for bromine or iodine and A1 and A2 have different meanings, are suitable as contrast media.

Abstract: Rare earth metal compounds are described which, due to their luminescence when irradiated with UV light, are suitable in particular for the marking of security-relevant items, such as documents or data carriers.

Abstract: The invention relates to metal complex compounds, contrast agents for MRI and in vivo NMR markers for NMR spectroscopy comprising said metal complex compounds and methods for in vivo determination of physiological parameters, e.g. enzyme activity or pH using said metal complex compounds.

Abstract: The present invention provides compounds of the formula X—R1-D-[Dpr, Orn or Lys](A)-R2(Z)-D-[Dpr, Orn or Lys](B)—R3(Y)—NR4R5; or R1(X)-D-[Dpr, Orn or Lys](A)-R2(Z)-D-[Dpr, Orn or Lys](B)—R3(Y)—NR4R5, in which X is a hard acid cation chelator, a soft acid cation chelator or Ac—, R1, R2 and R3 are independently selected from a covalent bond or one or more D-amino acids that can be the same or different, Y is a hard acid cation chelator, a soft acid cation chelator or absent, Z is a hard acid cation chelator, a soft acid cation chelator or absent, and A and B are haptens or hard acid cation chelators and can be the same or different, and R4 and R5 are independently selected from the group consisting of hard acid cation chelators, soft acid cation chelators, enzymes, therapeutic agents, diagnostic agents and H. The present invention also provides methods of using these compounds and kits containing the compounds.

Abstract: Substituted 1,4,7-triazacyclononane-N,N?,N?-triacetic acid compounds with a pendant donor amino group, metal complexes thereof, compositions thereof, and methods of use in diagnostic imaging and treatment of a cellular disorder.

Abstract: The present invention relates to a method for preparing neodymium-carbon-nanotube and a process for preparing 1,4-cis-polybutadiene utilizing the same and more particularly, neodymium-carbon-nanotube. Neodymium is introduced by coordination with carboxylic acid, which is formed on the surface of carbon nanotube. In 1,3-butadiene polymerization with the neodymium-catalyst comprising the neodymium-carbon nanotube, a particular halogen compound, and a particular organometallic compound in an appropriate ratio, high 1,4-cis polybutadiene having molecular weight of 10,000 to 2,000,000 is produced, which exhibits excellent mechanical properties such as elasticity and durability.

Abstract: The invention provides methods and compositions for molecular resonance imaging of membrane potential. The compositions comprise an indicator moiety attached through an optional linker to a macrocycle component that binds a lanthanide. The indicator moiety changes conformation in response to alterations in membrane potential and alters the interaction of the bound lanthanide with water. This alteration produces a detectable change in MRI signal , notably the T1 value. A preferred indicator moiety is spiropyran as it exhibits membrane-potential driven interconversions between the closed-ring spiropyran conformer and the extended merocyanine conformer. A preferred macrocycle is DO3A, known to bind gadolinium and an established MRI contrast agent. The methods of the invention comprise in vivo and in vitro uses of compositions of the invention to obtain MRI images that provide information about membrane potential.

Abstract: Substituted 1,4,7-triazacyclononane-N,N?,N?-triacetic acid compounds with a pendant donor amino group, metal complexes thereof, compositions thereof, and methods of use in diagnostic imaging and treatment of a cellular disorder.

Abstract: The present invention is directed, in general, to a contrast agent comprising a tetraazacyclododecane ligand and comprising a macrocyclic ring and a paramagnetic metal ion coordinated to the tetraazacyclododecane ligand. Pendent arms R, R?, R? and R?? attached to a ring nitrogen. The pendent arms have the general formula: ?C?HR1R2 and for three or more of the pendant arms a chirality of the carbon atoms C? are identical for each of three or more of the pendant arms. The R1 group is larger than hydrogen and R2 is selected from the group consisting of: an alcohol, amides, a carboxylate, phosphinates and a phosphonate. One or more substituents R6 is a group larger than a methyl group and is located on one or more ring carbons.

Abstract: The invention relates to crystalline lithium complexes of N-(1-hydroxymethyl-2,3-dihydroxypropyl)-1,4,7-triscarboxymethyl-1,4,7,10 tetraazacyclododecane, their production and the recovery of the salt-free gadolinium complex of N-(1-hydroxymethyl-2,3-dihydroxypropyl)-1,4,7-triscarboxymethyl-1,4,7,10 tetraazacyclododecane from the latter without the use of ion exchangers.

Abstract: Novel metal-chelate complexes comprising aminocarboxylate ligands including substituted aromatic amide moieties, such as those having the formula wherein R13, A1, R1 and R2 are as defined herein, are disclosed.

Abstract: The present invention provides methods of making porphyrins and related compounds such as chlorins by condensing suitable starting materials (e.g., a dipyrromethane-dicarbinol plus dipyrromethane) in a polar solvent in the presence of a Lewis acid. The reactions are preferably carried out in a manner that minimizes rearrangement of the reaction product.